Digitalis Trials
Cross-source consensus on Digitalis Trials from 1 sources and 5 claims.
1 sources · 5 claims
Comparisons
Background
Evidence quality
Highlighted claims
- The DIG trial found no all-cause mortality reduction from digoxin but did reduce hospitalization for worsening heart failure. — Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
- DIGIT-HF found a significant 15% reduction in all-cause death plus first heart failure admission with low-dose digitoxin. — Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
- DIGIT-HF enrolled a more advanced heart failure population than DECISION. — Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
- DECISION should be interpreted together with DIG and DIGIT-HF. — Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
- RATE-AF found similar quality-of-life effects for low-dose digoxin and bisoprolol, while digoxin performed better on several heart failure-related endpoints. — Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial